According to the financial report of CR Sanjiu on the first three quarters of 2012 published on October 30, CR realized a net profit of 740 million yuan in the first three quarters, a year-on-year growth of 25.8%. The earning on the capital is 0.87 yuan per share. The Company realized total revenue of 1.58 billion yuan in Q3, a year-on-year increase of 23%, and a net profit of 225 million yuan, a year-on-year increase of 23.5%.

The data published show that CR Sanjiu saw a steady growth in the first three quarters this year, strengthening its position as the leading enterprise in the field of domestic OTC. By further expanding business channels and the primary medical care market and promoting customer experience and implementing brand image building plans, CR Sanjiu achieved remarkably, with its OTC business steadily growing, the prescribed traditional Chinese medicine, antibiotics and medical care services rapidly growing and exceeding expectations.

In the capital market, the continued stable growth of CR Sanjiu also won the favor of major financial institutions, which keep close watch on CR Sanjiu for opportunities of cooperation. CR Sanjiu also performs well in the secondary market. In the third quarter of this year, stakes in Efund Value Growth Mixed Securities Investment Fund and the National Social Security Fund Portfolio 1 were significantly increased.